We are live on ! Find out more
AXDX icon

Accelerate Diagnostics

Delisted

AXDX was delisted on the 14th of May, 2025.

37 hedge funds and large institutions have $14.7M invested in Accelerate Diagnostics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

361% more capital inflows, than outflows

Capital inflows: $2.74M | Capital outflows: $595K

4.52% less ownership

Funds ownership: 22.3% → 17.79% (-4.5%)

26% less funds holding

Funds holding: 50 → 37 (-13)

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

62% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 21

Holders
37
Holders Change
-13
Holders Change %
-26%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
12
Closed
21
Calls
$1​K
Puts
–
Net Calls
+$1​K
Net Calls Change
+$14​K

AXDX Hedge Fund Activity: Q3 2023 in Review

37 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2023, worth a combined $14.7M — down 18% from $18M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of AXDX and 8 opened new positions — a net loss of 13 holders — while 12 trimmed existing stakes and 6 added.

The largest buyer was Cannell & Co, opening a new position worth an estimated $772K. The largest seller was Millennium Management, exiting entirely with an estimated $100K sold.

  • 37 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2023, down from 50 in Q2 2023.
  • Funds reported $14.7M of Accelerate Diagnostics stock for Q3 2023, down 18% quarter-over-quarter.
  • 8 funds opened new Accelerate Diagnostics positions in Q3 2023 and 21 closed out, a net change of -13 holders.
  • The largest Accelerate Diagnostics buyer in Q3 2023 was Cannell & Co, an estimated $772K added.
  • The largest Accelerate Diagnostics seller in Q3 2023 was Millennium Management, an estimated $100K sold.

Based on aggregated 13F filings for Q3 2023.